pentetic acid and edotreotide

pentetic acid has been researched along with edotreotide in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (33.33)	18.2507
2000's	5 (55.56)	29.6817
2010's	1 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bakker, WH; Béhé, M; Bernard, BF; Breeman, WA; de Jong, M; Jermann, E; Krenning, EP; Mäcke, HR; Powell, P; van der Pluijm, ME; Visser, TJ	1
Behe, M; Bucher, HC; Goetze, M; Heppeler, A; Jermann, E; Maecke, HR; Mueller-Brand, J; Otte, A; Roser, HW	1
Bakker, WH; Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Mäcke, H; Rolleman, EJ; Visser, TJ	1
de Jong, M; Krenning, EP; Kwekkeboom, D	1
Bohuslavizki, KH	1
Chen, CH; Hen, SL; Ho, YJ; Hsia, CC; Hung, GU; Lin, WY; Lin, YC; Luo, TY	1
de Jong, M; Forrer, F; Krenning, EP; Kwekkeboom, DJ; Valkema, R	1
Barone, R; Jamar, F; Konijnenberg, M; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S	1
Bares, R; Dudziak, K; Gallwitz, B; Häring, HU; Horger, M; Müssig, K; Oksüz, MO; Petersenn, S; Pfannenberg, C; Schulz, S; Ueberberg, B; Wehrmann, M	1

Reviews

2 review(s) available for pentetic acid and edotreotide

Article	Year
Peptide receptor imaging and therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10 Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2000
Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:1 Topics: Blood; Heterocyclic Compounds; Humans; Kidney; Liver; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pentetic Acid; Radioisotopes; Receptors, Peptide; Somatostatin; Time Factors	2007

Trials

1 trial(s) available for pentetic acid and edotreotide

Article	Year
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nuclear medicine communications, 2008, Volume: 29, Issue:3 Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radiation Dosage; Radiopharmaceuticals; Relative Biological Effectiveness; Somatostatin	2008

Article

Year

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.

Nuclear medicine communications, 2008, Volume: 29, Issue:3

Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radiation Dosage; Radiopharmaceuticals; Relative Biological Effectiveness; Somatostatin

2008

Other Studies

6 other study(ies) available for pentetic acid and edotreotide

Article	Year
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. European journal of nuclear medicine, 1997, Volume: 24, Issue:4 Topics: Animals; Indium Radioisotopes; Male; Octreotide; Pentetic Acid; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes	1997
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European journal of nuclear medicine, 1997, Volume: 24, Issue:7 Topics: Abdominal Neoplasms; Adult; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Yttrium Radioisotopes	1997
D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:12 Topics: Animals; Indium Radioisotopes; Kidney; Lysine; Male; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Yttrium Radioisotopes	1997
Somatostatin receptor imaging: current status and future perspectives. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:7 Topics: Gallium Radioisotopes; Humans; Indium Radioisotopes; Meningeal Neoplasms; Meningioma; Octreotide; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2001
A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors. The Journal of veterinary medical science, 2006, Volume: 68, Issue:4 Topics: Animals; Indium Radioisotopes; Male; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Tissue Distribution	2006
Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:8 Topics: Female; Humans; Immunohistochemistry; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Positron-Emission Tomography; Receptors, Somatostatin; Tomography, X-Ray Computed	2010